Evidence map›Paper›PMID 38976739›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.

Liying Shan, Wenmeng Wang, Lijuan Du, Dangdang Li, Yunxuan Wang, Yuyan Xie, Hongyan Li, Jiale Wang, Zhihao Shi, Yang Zhou and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. G-Quadruplexes: Structural Diversity and Emerging Roles in Biomolecular Condensation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Function ofOncology letters · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. HighCancers · 2025
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Liying Shan *Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Wenmeng Wang *College of Life Science, Northeast Forestry University, Harbin 150040, China.
Lijuan DuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Dangdang LiCollege of Life Science, Northeast Forestry University, Harbin 150040, China.ORCID 0000-0001-6407-9705
Yunxuan WangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Yuyan XieDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.ORCID 0009-0009-5640-6177
Hongyan LiDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Jiale WangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Zhihao ShiDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Yang ZhouDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Daling ZhuCollege of Pharmacy, Harbin Medical University (Daqing), Daqing 163319, China.
Guangchao SuiCollege of Life Science, Northeast Forestry University, Harbin 150040, China.ORCID 0000-0002-8164-5585
Fang LiuDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.

Funding

The Beijing Science and Technology Innovation Medical Development Foundation 81270113The Haiyan Foundation of Harbin Medical University Cancer Hospitalcancer h 91339107The National Cancer Centre Climbing Foundation NCC201908B11The National Natural Science Foundation of China 82273107
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death worldwide, but the underlying molecular mechanisms remain largely unclear. The transcription factor (TF) specificity protein 1 (SP1) plays a crucial role in the development of various cancers, including LUAD. Recent studies have indicated that master TFs may form phase-separated macromolecular condensates to promote super-enhancer (SE) assembly and oncogene expression. In this study, we demonstrated that SP1 undergoes phase separation and that its zinc finger 3 in the DNA-binding domain is essential for this process. Through Cleavage Under Targets & Release Using Nuclease (CUT&RUN) using antibodies against SP1 and H3K27ac, we found a significant correlation between SP1 enrichment and SE elements, identified the regulator of the G protein signaling 20 (RGS20) gene as the most likely target regulated by SP1 through SE mechanisms, and verified this finding using different approaches. The oncogenic activity of SP1 relies on its phase separation ability and RGS20 gene activation, which can be abolished by glycogen synthase kinase J4 (GSK-J4), a demethylase inhibitor. Together, our findings provide evidence that SP1 regulates its target oncogene expression through phase separation and SE mechanisms, thereby promoting LUAD cell progression. This study also revealed an innovative target for LUAD therapies through intervening in SP1-mediated SE formation.

Indexed as

Adenocarcinoma of LungGene Expression Regulation, NeoplasticLung NeoplasmsRGS ProteinsSp1 Transcription FactorAnimalsCell Line, TumorDisease ProgressionEnhancer Elements, GeneticHumansMicePhase SeparationRGS ProteinsSP1 protein, humanSp1 Transcription Factorliquid–liquid phase separationlung cancerRGS20SP1super-enhancer

Identifiers

PMID38976739
PMCPMC11260144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.